Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate
Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)
DOI: 10.1093/jac/dkag185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 22.05.2026. Verfasst von Stephanie Supparitsch und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria. Hauptthemen laut MEDLINE: Ceftazidime, Pseudomonas aeruginosa, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Peritoneal dialysis (PD) enables intraperitoneal antibiotic delivery, but the efficacy of ceftazidime/avibactam (CAZ/AVI) in PD fluid (PDF) is not well-characterized.
Objectives
To assess the in vitro activity of ceftazidime/avibactam against Pseudomonas aeruginosa in fresh PDF and patient-derived dialysate at isolate-specific MIC levels and at a clinically measured intraperitoneal peak concentration (Cmax).
Methods
MICs were determined for P. aeruginosa ATCC 27583 and nine clinical isolates using broth microdilution in CAMHB. Two isolates (123/19, 174/19) underwent time-kill experiments at MIC (8–16 µg/mL) and maximum peritoneal concentration (Cmax 64 µg/mL), with avibactam fixed at 4 µg/mL. Bacterial counts were evaluated over 24 h in CAMHB, icodextrin-containing PDF, and patient-derived dialysate (n = 4).
Results
Isolates showed variable growth. Ceftazidime/avibactam was bactericidal in CAMHB but only bacteriostatic in PDF and patient-derived dialysate (±1 log10 cfu/mL reduction at 8 h). No further reduction occurred at 24 h, even at Cmax.
Conclusions
Reduced bacterial growth in PDF is associated with diminished ceftazidime/avibactam activity, yielding primarily bacteriostatic effects. Single-dose intraperitoneal administration may be insufficient to eradicate P. aeruginosa, as Cmax concentrations failed to achieve ≥3 log10 cfu/mL reduction in vitro. These findings highlight potential limitations of ceftazidime/avibactam in PD-related infections and might guide future dosing strategies research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
- Department of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Alina Nussbaumer-Pröll
Zitieren
APA
Supparitsch, S., Vychytil, A., Zeitlinger, M., & Nussbaumer-Pröll, A. (2026). Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag185
Vancouver
Supparitsch S, Vychytil A, Zeitlinger M, Nussbaumer-Pröll A. Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag185
BibTeX
@article{Supparitsch2026,
author = {Supparitsch, Stephanie and Vychytil, Andreas and Zeitlinger, Markus and Nussbaumer-Pröll, Alina},
title = {Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {6},
doi = {10.1093/jac/dkag185}
}
EUVIMED